艾多沙班方案与维生素K拮抗剂方案在房颤患者冠状动脉支架置入成功后的比较(ENTRUST-AF PCI):一项随机、开放标签、3b期试验
ENTRUST-AF PCI是一项在18个国家186个中心进行的随机、多中心、开放标签、非劣效3b期试验,纳入1506例因稳定冠心病或急性冠脉综合征成功行PCI且需要口服抗凝的房颤患者,PCI后4小时至5天内按1:1随机接受艾多沙班(60mg每日一次,特定情况减至30mg)联合P2Y12抑制剂治疗12个月,或VKA联合P2Y12抑制剂及阿司匹林(100mg每日一次,1-12个月)。主要终点为12个月内大出血或临床相关非大出血的复合终点,艾多沙班组128/751例(17%,年化事件率20.7%) vs VKA组152/755例(20%,年化事件率25.6%),HR 0.83(95%CI 0.65-1.05),非劣效性P=0.0010(非劣效界值HR 1.20),优效性P=0.1154。结论认为艾多沙班方案在出血方面非劣效于VKA方案,缺血事件无显著差异。
要点
- 房颤患者成功PCI后4小时至5天内随机,艾多沙班组大出血或临床相关非大出血128/751例(17%,年化20.7%) vs VKA组152/755例(20%,年化25.6%),HR 0.83(95%CI 0.65-1.05),非劣效性P=0.0010(界值HR 1.20)。
- 艾多沙班标准剂量为60mg每日一次口服,若存在肌酐清除率15-50mL/min、体重≤60kg或联用特定强效P-糖蛋白抑制剂之一,减至30mg每日一次。
- VKA组三联方案中阿司匹林100mg每日一次口服,疗程1-12个月;艾多沙班组联合P2Y12抑制剂治疗12个月。
- 主要终点优效性检验P=0.1154,未达统计学显著;缺血事件两组无显著差异。
- 该方案适用于因稳定冠心病或急性冠脉综合征成功行PCI、需要口服抗凝的房颤患者,年龄至少18岁。
适用人群与场景
- 因稳定冠心病或急性冠脉综合征成功行PCI、需要口服抗凝的房颤患者,年龄至少18岁。
- PCI后4小时至5天内入组随机。
处置流程与药物剂量
- 艾多沙班组:艾多沙班60mg每日一次口服联合P2Y12抑制剂治疗12个月;若存在肌酐清除率15-50mL/min、体重≤60kg或联用特定强效P-糖蛋白抑制剂之一,艾多沙班减至30mg每日一次。
- VKA组:VKA联合P2Y12抑制剂及阿司匹林100mg每日一次口服,阿司匹林疗程1-12个月。
研究设计与关键结果
- 随机、多中心、开放标签、非劣效3b期试验,186个中心、18个国家,纳入1506例,随机至艾多沙班方案组(n=751)或VKA方案组(n=755),PCI至随机中位时间45.1小时(IQR 22.2-76.2)。
- 主要终点(12个月内大出血或临床相关非大出血复合终点):艾多沙班组128/751例(17%,年化事件率20.7%) vs VKA组152/755例(20%,年化事件率25.6%),HR 0.83(95%CI 0.65-1.05),非劣效性P=0.0010(非劣效界值HR 1.20),优效性P=0.1154。
- 缺血事件两组无显著差异。
证据类型、等级与局限
- 证据类型:随机、多中心、开放标签、非劣效3b期试验,采用盲法结局评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于因稳定冠心病或急性冠脉综合征成功行PCI且需要口服抗凝的房颤患者,艾多沙班联合P2Y12抑制剂方案在出血方面非劣效于VKA联合P2Y12抑制剂及阿司匹林方案,缺血事件无显著差异。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: We aimed to assess the safety of edoxaban in combination with P2Y12 inhibition in patients with atrial fibrillation who had percutaneous coronary intervention (PCI).
METHODS: ENTRUST-AF PCI was a randomised, multicentre, open-label, non-inferiority phase 3b trial with masked outcome evaluation, done at 186 sites in 18 countries. Patients had atrial fibrillation requiring oral anticoagulation, were aged at least 18 years, and had a successful PCI for stable coronary artery disease or acute coronary syndrome. Participants were randomly assigned (1:1) from 4 h to 5 days after PCI using concealed, stratified, and blocked web-based central randomisation to either edoxaban (60 mg once daily) plus a P2Y12 inhibitor for 12 months or a vitamin K antagonist (VKA) in combination with a P2Y12 inhibitor and aspirin (100 mg once daily, for 1-12 months). The edoxaban dose was reduced to 30 mg per day if one or more factors (creatinine clearance 15-50 mL/min, bodyweight ≤60 kg, or concomitant use of specified potent P-glycoprotein inhibitors) were present. The primary endpoint was a composite of major or clinically relevant non-major (CRNM) bleeding within 12 months. The primary analysis was done in the intention-to-treat population and safety was assessed in all patients who received at least one dose of their assigned study drug. This trial is registered with ClinicalTrials.gov, NCT02866175, is closed to new participants, and follow-up is completed.
FINDINGS: From Feb 24, 2017, through May 7, 2018, 1506 patients were enrolled and randomly assigned to the edoxaban regimen (n=751) or VKA regimen (n=755). Median time from PCI to randomisation was 45·1 h (IQR 22·2-76·2). Major or CRNM bleeding events occurred in 128 (17%) of 751 patients (annualised event rate 20·7%) with the edoxaban regimen and 152 (20%) of 755 patients (annualised event rate 25·6%) patients with the VKA regimen; hazard ratio 0·83 (95% CI 0·65-1·05; p=0·0010 for non-inferiority, margin hazard ratio 1·20; p=0·1154 for superiority).
INTERPRETATION: In patients with atrial fibrillation who had PCI, the edoxaban-based regimen was non-inferior for bleeding compared with the VKA-based regimen, without significant differences in ischaemic events.
FUNDING: Daiichi Sankyo.
参考来源
- Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019. PMID: 31492505. doi:10.1016/S0140-6736(19)31872-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。